Relationship between polymorphisms in thrombophilic genes and preeclampsia in a Brazilian population

Blood Cells, Molecules, and Diseases

Volumn 37, Issue 2, 2006, Pages 107-110

  Dalmaz C A ^a,b   Santos, K G ^a   Botton, M R ^a   Tedoldi, C L ^c   Roisenberg, I ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b Mestrado em Avaliacao de Impactos Ambientais em Mineracao Victor Barreto   (Brazil)

^c HOSPITAL NOSSA SENHORA DA CONCEIÇÃO   (Brazil)

Author keywords

Factor V Leiden; Methylenetetrahydrofolate reductase; Plasminogen activator inhibitor type 1 (PAI 1); Preeclampsia; Prothrombin

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5 LEIDEN; PLASMINOGEN ACTIVATOR; PROTHROMBIN;

ADULT; ARTICLE; BRAZIL; CONTROLLED STUDY; DISEASE ASSOCIATION; EVALUATION; FEMALE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; POPULATION GENETICS; PREECLAMPSIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR;

ADULT; ALLELES; BRAZIL; CASE-CONTROL STUDIES; FACTOR V; FEMALE; GENOTYPE; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MUTATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PRE-ECLAMPSIA; PREGNANCY; PROSPECTIVE STUDIES; PROTHROMBIN; RISK FACTORS; THROMBOPHILIA;

EID: 33748803599     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2006.07.005     Document Type: Article

References (23)

1. Geary M. The HELLP syndrome. Br. J. Obstet. Gynaecol. 104 (1997) 887-891
2. Roberts J.M., and Redman C.W. Pre-eclampsia: more than pregnancy induced hypertension. Lancet 341 (1993) 1447-1451
3. Kupferminc M.J. Thrombophilia and preeclampsia: the evidence so far. Clin. Obstet. Gynecol. 48 (2005) 406-415
4. Morrison E.R., Miedzybrodzka A.Z., Campbell D.M., et al. Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: results from a large population-based study and systematic review. Thromb. Haemost. 87 (2002) 779-785
5. Kujovich J.L. Thrombophilia and pregnancy complications. Am. J. Obstet. Gynecol. 191 (2004) 412-424
6. Robertson L., Wu O., Langhorne P., et al. Thrombophilia in pregnancy: a systematic review. Br. J. Haematol. 132 (2006) 171-196
7. American College of Obstetricians and Gynecologists. Diagnosis and management of preeclampsia. ACOG Pract. Bull. 33 (2002) 1-14
8. Lahiri Jr. D.K., and Nurnberger J.I. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res. 19 (1991) 5444
9. Frosst P., Blom H.J., Milos R., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 10 (1995) 111-113
10. Poort S.R., Rosendaal F.R., Reitsma P.H., and Bertina R.M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88 (1996) 3698-3703
11. Bertina R.M., Koeleman B.P.C., Koster T., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369 (1994) 64-67
12. Mansfield M.W., Stickland M.H., and Grant P.J. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor type 1 in Caucasian patients with non-insulin-dependent diabetes mellitus. Thromb. Haemost. 74 (1995) 842-847
13. Daválos I.P., Moran M.C., Martínez-Abundis E., et al. Methylenetetrahydrofolate reductase C677T polymorphism and Factor V Leiden variant in Mexican women with preeclampsia/eclampsia. Blood Cells, Mol. Dis. 35 (2005) 66-69
14. Pabinger I., and Vormittag R. Thrombophilia and pregnancy outcomes. J. Thromb. Haemost. 3 (2005) 1603-1610
15. Grandone E., Margaglione M., Calaizzoj D., et al. Prothrombotic genetic risk factors and the occurrence of gestational hypertension with or without proteinuria. Thromb. Haemost. 81 (1999) 349-352
16. Rees D.C., Cox M., and Clegg J.B. World distribution of factor V Leiden. Lancet 6 (1995) 74-79
17. Kang S.S., Zhou J., Wong P.W.K., et al. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary disease. Am. J. Hum. Genet. 48 (1991) 536-545
18. Doggen C.J., Bertina R.M., Cats V.M., et al. The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with myocardial infarction. Thromb. Haemost. 82 (1999) 115-120
19. Segui R., Estelles A., Mira Y., et al. PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects. Br. J. Haematol. 111 (2000) 122-128
20. de Maat M.P.M., Jansen M.W.J.C., Hille E.T.M., et al. Preeclampsia and its interaction with common variants in thrombophilia genes. J. Thromb. Haemost. 2 (2004) 1588-1593
21. Yamada N., Arinami T., Kobayashi K.Y., et al. The 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene is associated with severe preeclampsia. J. Hum. Genet. 45 (2000) 138-141
22. Fabbro D., D'Elia A.V., Spizzo R., et al. Association between plasminogen activator inhibitor 1 gene polymorphisms and preeclampsia. Gynecol. Obstet. Invest. 56 (2003) 17-22
23. Kim Y.J., Williamson R.A., Murray J.C., et al. Genetic susceptibility to preeclampsia: roles of cytosine-to-thymine substitution at nucleotide 677 of the gene for methylenetetrahydrofolate reductase, 68-basepair insertion at nucleotide 844 of the gene for cystathione β-synthase, and factor V Leiden mutation. Am. J. Obstet. Gynecol. 184 (2001) 1211-1217